To test how IFN-I signaling contributes to the protective effects of STING agonists in the bone cancer model, we again introduced LLC cells into the femora of Ifnar1+/+ (WT) or Ifnar1−/− (KO) mice to establish the bone cancer models in mice with deficient host IFN-I signaling. This evidence concerns the gene IFNAR1 and bone neoplasm.